Compare Biogen Inc (BIIB) vs Teradyne, Inc. (TER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Teradyne, Inc. — how do they compare? Biogen Inc trades at $195.34 (market cap $28.34B), while Teradyne, Inc. trades at $330.58 (market cap $55.30B). The key difference: Teradyne, Inc. is the larger of the two by market cap, and Teradyne, Inc. pays a 0.15% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | TER | |
|---|---|---|
Market Cap | $28.34B | $55.30B |
Sector | Health | Technology |
52-Week High | $216.63 | $483.84 |
52-Week Low | $122.68 | $90.15 |
Enterprise Value | $30.62B | $55.13B |
Dividend Yield | — | 0.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
Teradyne (TER) trades at $341.11, down 5.14% over 24 hours, with a bearish technical signal. The stock shows strong fundamentals with three consecutive quarterly earnings beats and robust profitability margins. Recent news highlights AI-driven demand boosting semiconductor testing revenue, positioning TER as a key player in robotics and AI infrastructure. Cash flow trends indicate consistent operational strength despite negative net cash flow from aggressive investing activities.
Outlook remains positive with a consensus price target of $453.60, implying 33% upside. Risks include high valuation multiples and semiconductor cycle volatility. Analyst sentiment is strongly bullish with 64.5% buy ratings, supported by expanding AI and data center markets driving long-term growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →
